Active clinical trials for "Joint Diseases"

Our investigation was a prospective cross-sectional survey evaluating the patient experience to new patients that presented to an outpatient private practice specialized in total joint reconstruction. New patients seeing a PA during their initial visit were randomized to intervention and control groups and all were given a descriptive survey at checkout. Inclusion criteria (1) new patient (2) English speaking (3) appointment with PA. There was no exclusion criteria. Eligible patients were randomized to the intervention group (received biosketch card) or the control group (no card) using random number generator. Patients within the intervention group received a biosketch card during rooming, pre-clinician encounter, and were not informed about involvement. Both groups received standard care that was independent of the study. To blind the outcome measure, the research assistant did not explain the reason for the card upon rooming. The provider PA was not informed which patient received the card. Upon discharge, the patient completed a five-question survey regarding the clinic visit.

The purpose of this study is to compare injecting local anesthetic (numbing medication) in different patterns around a major nerve in the leg. Patients who undergo surgery to the lower leg and/or foot are usually offered the option of a nerve block to help with pain control after surgery. A nerve block involves injecting local anesthetic (numbing medicine) by a nerve or nerves that provide sensation to the area where surgery will be performed. The local anesthetic (numbing medication) numbs up the area where the surgery is performed and helps decrease the amount of pain felt after surgery. The local anesthetic (numbing medication) can be injected in various patterns by a nerve, such as in one spot by a nerve or completely surrounding a nerve. The local anesthetic will be either injected around the sciatic nerve or will injected in a way that will split the sciatic nerve into the two component nerves that make it up, the tibial and sciatic, and surrounds each nerve. The hypothesis is that subjects in the group that local anesthetic is injected in a pattern that separates the sciatic nerve into the two component nerves may have a faster onset time of regional anesthesia and block success than subjects in the group that have the local anesthetic injected at around the nerve.

Introduction. The development of joint hemorrhages in patients with congenital coagulopathies favor the development of an intra-articular, degenerative and progressive lesion (hemophilic arthropathy). Pain is one of the main clinical manifestations of hemophilic arthropathy and is related to the development of disability and a worse quality of life. Objective. Observe the characteristics of pain, coping models and the perception of quality of life in patients with congenital coagulopathies. Study design. Observational, cross-sectional and multi-center study. Method. 80 patients with congenital coagulopathies (hemophilia A and B, and von Willebrand's disease), of legal age, will be included in the study. Patients will be recruited in six centers, from different regions of Spain. The study variables and measurement instruments used will be: pain perception (numerical pain scale, Tampa Scale of kinesiophobia and Pain Catastrophizing Scale); perception of quality of life (Short Form -36 questionnaires); anxiety (State-Trait Anxiety Questionnaire); coping strategies (Coping Strategy Questionnaire); and disease perception (Illness behaviour questionnaire and Revised Illness Perception Questionnaire). A descriptive statistical analysis of the dependent and independent variables will be carried out. In the same way, the correlations between the variables and the characteristics of the subjects will be analyzed according to age, the type of coagulopathy and the degree of sequelae. Expected results. Observe the characteristics of pain, its coping models and its implication in the quality of life in patients with congenital coagulopathies, and evaluate the independent variables related to the perception of pain.

Sacroiliac joint dysfunction (SJD) is a common problem in individuals with lumbar herniation nucleus pulposus (LHNP) plus back pain. It is important to determine the effects of SJD on the gait characteristics in individuals with LHNP.Twelve individuals with LHNP (control group) and six individuals with LHNP plus SJD (study group) will be the participants of the study. Gait characteristics of participants will be evaluate with treadmill. Participants will walk at their self-selected speed for six minutes and data from 2nd minutes to 4th minutes were selected for statistical analyses. Gait speed, cadance, step lengths, time on each foot and step length variabilities will be recorded.

The purpose of the study is the evaluation of the clinical and radiological short- to long-term safety and performance of the RM Pressfit vitamys cup. The data will be used for an ongoing evaluation of the product safety and performance.

The project's primary purpose is to test the hypothesis that oral administration of a low single dose of β-antagonist propranolol (40 mg) reduces pain sensitivity in patients with masticatory muscle pain.

This study is a randomized controlled study. 75 patients between the ages of 20-50 who were diagnosed with sacroiliac joint dysfunction will be included in the study. 25 patients will be given a home exercise program that strengthens the waist and hip girdle (to be shown once in the hospital by a physiotherapist and the form of the exercises will be given), 25 patients will be given kinesiology taping with inhibition technique with the exercise program, and 25 patients will be given kinesiology taping with fascia correction technique with the exercise program. Patients will do the exercises once a day for 1 month. In kinesiology taping with the inhibition method, an I-shaped tape of 15-20 cm in length will be applied on the sacroiliac joint on both sides without stretching the ends with 50% stretching in the middle. In addition, a 25-30 cm long I band will be applied over the right spina iliaca posterior superior, towards the left spina iliaca posterior superior. In the facia correction technique, 2 bands with no cut ends, a 10-15 cm web-shaped band divided into 4 or 5 parts with a width of 1-15 cm will be applied cross over the sacroiliac joint, without stretching the ends with 50% stretching in the middle. Gillet test (evaluation of sacroiliac joint movement with single hip flexion), Gaenslen test (pain provocation with passive hip flexion), Patrick test (provocation of pain with hip flexion, abduction and external rotation), standing flexion test (evaluation of sacroiliac joint movement with forward flexion), sacroiliac compression and distraction test (provocation of pain with anterior pelvic compression or distraction), long sitting test (pain in the sacroiliac joint after sitting for more than 30 minutes), posterior shear test (provocation of pain with hip flexion and adduction) will be applied to the patients. The patients' resting and moving pain levels will be measured using the Visuel Analog Scale (VAS). Pain duration in the last week will be questioned and noted. Global Assessment of the Patient's Self within the last 1 week will be made over VAS. Oswestry Disability Index (ODI) will be applied to determine the level of disability. Evaluations will be made before, 15 days after and 1 month after treatment.

Hemophilia is a constitutional coagulation disorder responsible for a hemorrhagic phenotype in patients from an early age. Hemarthrosis is one of the most frequent complications in hemophiliacs and leads to the development of severe and early arthropathy, sometimes as early as childhood. To date, there is no curative treatment for these joint disorders and preventive treatments are insufficient to completely prevent joint degradation. Mesenchymal stem cells have been shown to be of therapeutic interest in the management of pathologies such as osteoarthritis and inflammatory arthritis through their anti-inflammatory, regenerative and anti-apoptotic effects. Hemophilic arthropathy is a separate condition at the border of these two diseases Our study aim to show pre-clinical interest of mesenchymal stem cell therapy in hemophilic arthropathy

The study will take place in Egypt. Postgraduate students from different faculties of the Egyptian Universities will participate. The study will begin in Decemberr 2020.

The prevalence of HCV infection in Egypt is 14.7%. HCV is both a hepatotropic and a lymphotropic virus, it may exert a chronic stimulus on the immune system with both T and B lymphocyte alterations. In addition to cryoglobulinaemic vasculitis, HCV may trigger different immune-mediated extrahepatic disorders. A variable combination of HCV with other unknown enviromental and/or hostgenetic cofactors may lead to different clinical phenotypes that characterise HCV syndrome. Patients who have HCV -related arthropathy are accounted for by 2 clinical subsits: Rheumatoid-like arthritis and Cryoglobulin-related arthritis. Patients with mild arthritis, conservative manegement using analgesics with anti- inflammatory activity is recommended. In patients who have contraindications to their use, short term low dose prednisone is an option. In HCV infection with concomitant RA, ACR guidelines published in 2008 provided recommendations pertaining to these of DMARDs that are based on the severity of liver disease using the child- pugh- turcotte classification. For patients with severe cryoglobulinaemia such as severe debilitating disease or systemic in improvement, a combination of immunosuppressive and antiviral therapy is preferred. It has been found that antiviral therapy with interferon immunosuppressive and antiviral therapy is preferred. It has been found that antiviral therapy with interferon improves the musculoskeletal manifestations in HCV arthropathy. The DIrect antiviral agents seems very promising in treatment of HCV arthropathy. As HCV genotype 4 is the most common genotype in Egypt, the effective optional antiviral agents are sofosbuvir, daclatasvir, ledipasvir, paritaprevir, velpatasvir, ombitasvir and simeprevir.